A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol
- PMID: 1972557
A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol
Abstract
In this double blind study, the cardiovascular and hypokalaemic effects of equal doses of inhaled pirbuterol and salbutamol were compared in eight healthy volunteers. Increasing doses of 200, 400, 600 and 800 micrograms (total dose 2000 micrograms) were given from a metered dose inhaler at 15 min intervals, followed by measurement of heart rate, blood pressure, total electromechanical systole (QS2I) (as a measure of inotropic response) and plasma potassium (K+) concentration 15 min after each inhalation. After inhalation of the highest concentration, salbutamol resulted in a greater increase in heart rate (10.5 bpm vs 4.4 bpm, p less than 0.0007), and reduction in QS2I (-25.4 ms vs -9.6 ms, p less than 0.0001) than pirbuterol. There were no significant differences in changes in systolic blood pressure (1.9 mmHg vs 6 mmHg, p = 0.27), diastolic blood pressure (-5.8 mmHg vs -3.9 mmHg, p = 0.64) or plasma K+ (-0.21 mmol/L vs -0.15 mmol/L, p = 0.57). We conclude that the new beta-2 adrenergic agonist pirbuterol is at least as beta-2 selective as salbutamol when administered by repeated inhalation in healthy volunteers.
Similar articles
-
A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol.Eur Respir J. 1993 Feb;6(2):204-10. Eur Respir J. 1993. PMID: 8095240 Clinical Trial.
-
Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol.Chest. 1996 Apr;109(4):957-62. doi: 10.1378/chest.109.4.957. Chest. 1996. PMID: 8635377 Clinical Trial.
-
Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.Thorax. 1989 Feb;44(2):136-40. doi: 10.1136/thx.44.2.136. Thorax. 1989. PMID: 2928998 Free PMC article. Clinical Trial.
-
Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease.Drugs. 1985 Jul;30(1):6-21. doi: 10.2165/00003495-198530010-00002. Drugs. 1985. PMID: 2863125 Review.
-
Pirbuterol hydrochloride: evaluation of beta adrenergic agonist activity in reversible obstructive pulmonary disease and congestive heart failure.Pharmacotherapy. 1984 Jan-Feb;4(1):1-10. doi: 10.1002/j.1875-9114.1984.tb03301.x. Pharmacotherapy. 1984. PMID: 6142449 Review.